Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

被引：7
|
作者：
Huang, Linjuan [1 ,2 ,3 ,4 ]
Zhang, Jing [1 ,2 ,3 ,4 ]
Deng, Youling [1 ,2 ,3 ,4 ]
Wang, Hao [4 ,5 ,6 ]
Zhao, Piao [1 ,2 ,3 ,4 ]
Zhao, Guozhi [1 ,2 ,3 ,4 ]
Zeng, Wei [4 ,7 ]
Wang, Yonghui [4 ,8 ]
Chen, Connie [4 ]
Wagstaff, William [4 ]
Haydon, Rex C. [4 ]
Reid, Russell R. [4 ,9 ]
He, Tong-Chuan [4 ,10 ]
Shen, Le [4 ,10 ]
Luu, Hue H. [4 ]
Zhao, Ling [1 ,2 ,3 ,4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400046, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400046, Peoples R China
[4] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA
[5] Chongqing Med Univ, Minist Educ, Sch Lab Med, Key Lab Diagnost Med, Chongqing 400016, Peoples R China
[6] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China
[7] Jianghan Univ, Affiliated Hosp 2, Dept Neurol, Wuhan 430050, Hubei, Peoples R China
[8] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China
[9] Univ Chicago, Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA
[10] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA
来源：
GENES & DISEASES | 2023年 / 10卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Chemotherapy resistance; Cisplatin; Drug repurposing; Niclosamide; Ovarian cancer; MESENCHYMAL STEM-CELLS; BMP9-INDUCED OSTEOGENIC DIFFERENTIATION; SUPPRESSES TUMOR-GROWTH; WNT/BETA-CATENIN; ANTIHELMINTHIC NICLOSAMIDE; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; INHIBITION; PATHWAY; PROLIFERATION;
D O I：
10.1016/j.gendis.2022.12.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Ovarian cancer (OC) is one of the most lethal malignancies of the female reproduc-tive system. OC patients are usually diagnosed at advanced stages due to the lack of early diag-nosis. The standard treatment for OC includes a combination of debulking surgery and platinum-taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tu-mors after an initial response. Thus, there is an unmet clinical need to develop new therapeu-tic agents to overcome the chemoresistance of OC. The anti-parasite agent niclosamide (NA) has been repurposed as an anti-cancer agent and exerts potent anti-cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic
引用
收藏
页码：1687 / 1701
页数：15
相关论文
共 50 条
  • [1] APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
    Mohell, N.
    Alfredsson, J.
    Fransson, A.
    Uustalu, M.
    Bystrom, S.
    Gullbo, J.
    Hallberg, A.
    Bykov, V. J. N.
    Bjorklund, U.
    Wiman, K. G.
    CELL DEATH & DISEASE, 2015, 6 : e1794 - e1794
  • [2] APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
    N Mohell
    J Alfredsson
    Å Fransson
    M Uustalu
    S Byström
    J Gullbo
    A Hallberg
    V J N Bykov
    U Björklund
    K G Wiman
    Cell Death & Disease, 2015, 6 : e1794 - e1794
  • [3] Overcoming platinum resistance in ovarian cancer with niclosamide
    Arend, Rebecca C.
    Gangrade, Abhishek
    Haygood, Christen L. Walters
    Kurpad, Chandrika
    Metge, Brandon J.
    Samant, Rajeev S.
    Li, Pui-Kai
    Li, Yonghe
    Bhasin, Deepak
    Landen, Charles
    Alvarez, Ronald
    Straughn, J. Michael
    Buchsbaum, Donald J.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [4] Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells
    Horvath, Viktor
    Blanarova, Olga
    Svihalkova-Sindlerova, Lenka
    Soucek, Karel
    Hofmanova, Jirina
    Sova, Petr
    Kroutil, Ales
    Fedorocko, Peter
    Kozubik, Alois
    GYNECOLOGIC ONCOLOGY, 2006, 102 (01) : 32 - 40
  • [5] Salidroside overcomes cisplatin resistance in ovarian cancer via the inhibition of CRNDE-mediated autophagy
    Yu, Ge
    Nanding, Abiyasi
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2024, : 3097 - 3116
  • [6] Focal adhesion kinase (FAK) inhibition overcomes cisplatin-resistance in epithelial ovarian cancer
    Bean, L. M.
    Sulzmaier, F. J.
    Anderson, K. M.
    Tancioni, I.
    Kolev, V.
    Plaxe, S. C.
    McHale, M. T.
    Schlaepfer, D. D.
    Pachter, J. A.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 97 - 98
  • [7] Cisplatin resistance in human cervical, ovarian and lung cancer cells
    Jianli Chen
    Charalambos Solomides
    Hemant Parekh
    Fiona Simpkins
    Henry Simpkins
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 1217 - 1227
  • [8] Cisplatin resistance in human cervical, ovarian and lung cancer cells
    Chen, Jianli
    Solomides, Charalambos
    Parekh, Hemant
    Simpkins, Fiona
    Simpkins, Henry
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1217 - 1227
  • [9] Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways
    Huang, Linjuan
    Zhao, Ling
    Zhang, Jing
    He, Fang
    Wang, Hao
    Liu, Qing
    Shi, Deyao
    Ni, Na
    Wagstaff, William
    Chen, Connie
    Reid, Russell R.
    Haydon, Rex C.
    Luu, Hue H.
    Shen, Le
    He, Tong-Chuan
    Tang, Liangdan
    AGING-US, 2021, 13 (13): : 17407 - 17427
  • [10] Targeting mitochondria overcomes resistance to cisplatin-induced apoptosis of high grade serous ovarian cancer
    Kleih, M.
    Boepple, K.
    Gaissler, A.
    Dong, M.
    Heine, S.
    Essmann, F.
    Aulitzky, W. E.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 : S39 - S39
12345